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eginning in the early 1800s, routine weighing of newborns began in British lying-in hospitals, with some American maternity hospitals following by midcentury. 1 By 1900, birthweight was the most common quantitative measure available for evaluating individual fetal growth, although it is actually a measure of size. 2 This availability of birthweight led to its use in establishing relationships between obstetrical, pediatric, and neurobehavioral variables beginning in the late 1940s. 1 Birthweight as the surrogate for fetal growth was described in the classic paper of Battaglia and Lubchenco, 3 which introduced the classification system still in use today. This system categorizes neonates with birthweights below the 10th percentile for gestational age as small for gestational age (SGA), those with birth weights between the 10th and 90th percentiles as appropriate for gestational age (AGA), and those above the 90th percentile as large for gestational age (LGA). [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] These category boundaries were justified only by the observation that 10th percentile values were similar in different studies. 3 However, this system provided a means for relating size and preterm birth to neonatal mortality. [13] [14] [15] [16] Given this focus on birthweight as an indicator of fetal growth, it is not surprising that with the introduction of ultrasound into obstetrical practice in the 1970s, estimating fetal weight (because it cannot be measured directly) became a primary subject for investigation. [17] [18] [19] [20] [21] [22] [23] [24] This has led to the development of numerous formulas for estimating fetal weight. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] parameter that describes growth is velocity (the general formula for velocity is distance divided by time interval).
Obstetricians studying fetal growth often refer to this measurement as growth velocity. 43, 44 Several studies have characterized the growth velocities of different parameters (eg, abdominal circumference, estimated fetal weight), [45] [46] [47] [48] [49] [50] [51] [52] and this was largely pioneered by the studies of Owen and colleagues. 43, 44, [53] [54] [55] [56] [57] [58] [59] [60] Accumulating evidence suggests that abnormal fetal growth velocity of the abdominal circumference is associated with perinatal morbidity, in both SGA and LGA infants. 61, 62 The most recent evidence in support of this comes from a large, prospective cohort study of unselected nulliparous women with a single viable gestation who underwent a dating ultrasound examination (typically at 10e14 weeks) and then subsequent examinations at 20, 28, and 36 weeks of gestation. 62, 63 Among SGA neonates with an estimated fetal weight (EFW) less than the 10th percentile, those with an abdominal circumference velocity at the lowest decile (ie, abnormal) were at an increased risk for neonatal morbidity (risk ratio [RR], 3.9; 95% confidence interval [CI], 1.9e8.1) when compared with those with a normal abdominal circumference growth velocity. 62 Neonatal morbidity was defined as a 5 minute Apgar <7, cord blood pH <7.1, base deficit <10 mmol/L, or admission to the neonatal unit at term. Adverse outcomes were defined as stillbirth, term neonatal death, hypoxic ischemic encephalopathy, use of inotropes, mechanical ventilation, or metabolic acidosis.
These results provide compelling evidence that growth deceleration is more important than smallness in the prediction of neonatal morbidity. The importance of this information is strengthened by the fact that about 70% of fetuses diagnosed as SGA did not have an abnormal abdominal circumference growth velocity. It is interesting that suboptimal growth velocity of the abdominal circumference was associated with adverse neonatal outcome, while the results of umbilical or uterine artery Doppler velocimetry were not. 62 The importance of growth velocity is not limited to fetal growth restriction. Indeed, in a different study, Sovio et al 61 evaluated 117 LGA infants (birthweight greater than the 90th percentile). The sensitivity of estimated fetal weight in the detection of neonatal LGA was 38% (67 of 177). Importantly, in LGA fetuses with increased abdominal circumference growth velocity, there was a doubling in the risk of any neonatal morbidity (RR, 2.0, 95% CI, 1.1e3.6; P ¼ .04) and greater than 6-fold risk of severe adverse neonatal outcome (RR, 6.5; 95% CI, 2.0e21.1; P ¼ .01). 61 Neonatal morbidity was defined as a 5 minute Apgar <7, cord blood pH <7.1, base deficit <10 mmol/L, or admission to the neonatal unit at term. Adverse outcomes were defined as stillbirth, term neonatal death, hypoxic ischemic encephalopathy, use of inotropes, mechanical ventilation, or metabolic acidosis. Sonographic LGA was associated with a 10-fold risk and the combination of LGA and top decile of abdominal circumference growth velocity was associated with a greater than 20-fold risk. The associations remained very similar after adjustments for preexisting diabetes and gestational diabetes. 61 Therefore, in light of these observations, an emerging body of evidence has coalesced to support the importance of evaluating fetal growth velocity. [45] [46] [47] [48] [49] [50] [51] [52] 64 What is measured clinically, and their associated standards, has focused on detecting smallness or largeness at birth (SGA or LGA). Recent standards generated by various groups that have studied fetal size longitudinally 24, 33, 65 have not provided data on fetal growth velocity 83 Deter. Individualized growth assessment for fetal and neonatal evaluations. Am J Obstet Gynecol 2018.
FIGURE 2
Second-and third-trimester abdominal circumference by individualized growth assessment Individualized size trajectory is specified by the second-trimester abdominal circumference growth velocity. First, data points (red dots) are used to determine the slope (growth velocity) of the solid line. Next, the predicted third trimester trajectory (dashed line) is generated by a model derived from the second-trimester growth velocity. The black dots represent subsequent measurements superimposed on the predicted line. The shaded area is the abdominal circumference reference range obtained from fetuses with normal neonatal growth outcomes.
and its relationship with neonatal morbidity at the time of this publication.
Such velocity standards are expected to be forthcoming. Yet they reflect population standards rather than individualized growth standards for a particular fetus/neonate. 24, 33, 65, 66 The method that we describe herein uses fetal growth velocity that is personalized for an individual fetus/neonate. This is possible by generating a mathematical model based on an early trajectory of growth, which allows estimation of growth potential.
This article provides the conceptual framework for the individualized growth assessment of the fetus/neonate coupled with a practical and freely available software that allows implementation of this method for clinical and research purposes.
The optimal assessment of fetal/ neonatal growth We propose that an optimal method should address a few simple clinical criteria whose validity can be easily verified by any clinician in his/her medical practice:
All patients are different and must be evaluated on an individualized basis. Medical conditions evolve over time, and therefore, serial evaluations are needed. Abnormalities manifest themselves differently among individuals, so a set of tests is required for proper evaluation.
Application of these fundamental principles can be used to specify a fetal/ neonatal growth evaluation system with the following characteristics:
(1) Estimation of growth potential. Fetal growth restriction is generally defined as a failure to achieve such potential 67, 68 (the opposite applies to macrosomia). However, the student of this subject will note that after such statement is made, very few authors have attempted to measure growth potential. Individualized assessment of fetal growth and neonatal growth outcome requires knowing what values a Fetal growth evaluation using %Dev and %Dev p
The calculation of %Dev and its associated %Dev p are defined in the figure. The %Dev compares the measured and predicted parameter values. Pathological percent deviations can be positive (upper row, possible macrosomia) or negative (lower row, fetal growth restriction). The %Dev p quantifies growth pathology by indicating how far the %Dev is outside its age-specific reference range (located between the vertical dashed lines). The categories within the shaded area were assigned a value of zero because they provide no information on the growth pathology being studied. Neonatal growth evaluation using GPRI and pGPRI
The calculation of GPRI and its associated pGPRI are defined in the figure. The GPRI compares the measured and predicted birth characteristic values. Pathological GPRI can be positive (upper row, possible macrosomia) or negative (lower row, fetal growth restriction). The pGPRI quantifies neonatal growth pathology by indicating how far the GPRI is outside its reference range. The categories within the shaded area were assigned a value of zero because they provide no information on the growth pathology being studied. 24, 33, 34, 65, 66, [69] [70] [71] [72] [73] However, no information on individual growth potential is available in such assessments and the variability because of differences in growth potential is part of normal variability.
It is generally assumed that population-based percentile lines are the expected trajectories of normally growing fetuses. Yet this assumption produces significantly larger prediction errors than trajectories derived from individual growth potential estimates in the same fetuses. 74 Several investigators have described improvement in the prediction of adverse outcomes by customizing birthweight percentiles 70, [75] [76] [77] [78] [79] [80] and several papers in this issue of the Journal describe customization in detail as well as the pros and cons of this approach. Customization differs from individualized assessment in that it is carried out with only weight and known maternal determinants of growth. Individualized assessment uses multiple anatomical parameters and empirical measures of growth potential, which reflect both known and unknown growth determinants.
Because only 1 parameter is generally used in clinical medicine to monitor growth (eg, abdominal circumference or estimated fetal weight), any abnormality sparing this parameter would not be detected. 81 There is evidence that individualized growth assessment (IGA) can distinguish normally growing small fetuses/neonates from those that have true growth restriction. 82 For example, it is noteworthy that 42% (53 of 126) of SGA singletons diagnosed using conventional methods were actually growing normally, based on prenatal and postnatal individualized growth assessments (see the following paragraph for a complete description of IGA) 82 ( Figure 1 ).
Individualized growth assessment
A method that assesses fetal growth potential, an unmet need in our discipline, is individualized growth assessment. This method establishes standards for each anatomical parameter in a fetus or neonate (an individual is its own control) and identifies growth pathology as deviations from these standards, using Neonatal growth outcomes using mNGAS and pNGAS
This figure demonstrates how the mNGAS and its associated pNGAS are calculated. The mNGAS provides a composite measure of neonatal growth outcome based on 5 weighted GPRI values. The weights give the importance of specific GPRI values in separating growth-restricted, normal, and macrosomic neonates. The pNGAS quantifies growth outcome pathology by indicating how far the mNGAS is beyond its reference range (determined in neonates with normal growth outcomes). The categories within the shaded area were assigned a value of zero because they provide no information on the growth pathology being studied.
GPRI, growth potential realization index; mNGAS, modified neonatal growth assessment score; pNGAS, pathological modified neonatal growth assessment score. either a single parameter or a set of parameters.
Concepts of normal fetal/neonatal growth assessment using individualized growth assessment.
(1) Fetal growth potential. In contrast to conventional methods, individualized growth assessment obtains empirical estimates of growth potential for all measured anatomical parameters in an individual fetus. We have proposed that fetal growth potential can be estimated by calculating second-trimester growth velocities for the reasons listed in Table 1 . 83 Because second-trimester fetal growth is quite linear (or can be linearized by mathematical transformation), 83, 84 growth velocities for all measurements can be determined using linear regression. Growth potential estimates obtained from these empirically determined growth velocities reflect all known and unknown determinants of growth operating in the second trimester. Because second-trimester growth can be evaluated based on several parameters, there is more than 1 growth potential [one for each growth parameter].
To be valid representatives of inherent growth potential, velocity measurements must be obtained in the absence of fetal growth pathology. Typically this occurs in the early second trimester. Optimal implementation of IGA requires at least 2 sets of fetal biometric measurements between 14 and 28 weeks, with an interval of at least 2e3 weeks during a period of normal growth. Ultrasound examinations can be performed at any time within this timeframe. It should be emphasized that the earlier the examination is performed, the less likely that a fetal growth disorder has begun that could alter model specification.
(2) Fetal growth start point. Human biological studies indicate that an individual starts as a single cell and through embryogenesis becomes an organism with 7500 named parts. 85 These embryonic biometric parameters can be detected for the first time at different points in development. 86 For any anatomical structure, its duration of growth cannot begin until it exists. The use of menstrual age to assess fetal age instead of duration of growth creates a challenge because growth of anatomical parameters cannot start 2 weeks before there is a fertilized zygote. Therefore, defining duration of growth requires determination of a start point, 84 which is the point at which an anatomical parameter can first be identified (see the Glossary for Start Point determination). (3) Modeling of fetal size. Individualized growth assessment uses a mathematical function [P ¼ c(t) kþst ] developed by Ivar Rossavik to model fetal growth. 87 The model defines the relationship between the size of an anatomical parameter and the duration of fetal growth. This relationship is specified by coefficients c, k, and s. Because this function is closely related to fractional polynomials, 88 there is great flexibility in fitting individual size trajectories. 87 This particular mathematical function has been compared with population percentile lines and conditional probability methods for generating individualized fetal growth trajectories and found to be more accurate. 82 The model coefficients are likely to have biological meaning, c being related to the growth potential, k related to the anatomical characteristics of the parameter being measured, and s related to a growth controller, such as the insulin-like growth factor system 89 (for more details about the method and calculation of the coefficients, see the Glossary). (4) Size model specification. Model specification requires obtaining The e%Dev p values for AC at different menstrual ages were averaged to give the eacPGAS that quantifies AC growth pathology in the third trimester. For this fetus, the eacPGAS is e2.4%, which indicates growth restriction. Example 2: The e%Dev p values at 1 time point (32 weeks) for HC, AC, FDL and EFW were averaged to give a composite parameter (eicPGAS) that quantifies overall growth pathology at 32 weeks. 94 For this fetus, the eicPGAS is e2.5%, which indicates growth restriction at 32 weeks.
AC, abdominal circumference; eacPGAS, negative abdominal circumference PGAS; %Dev p , pathological percent deviation; e%Dev p , negative pathological percent deviation; EFW, estimated fetal weight; FDL, femur diaphysis length; HC, head circumference; icPGAS, individual composite prenatal growth assessment score; mPGAS, modified prenatal growth assessment scores.
Deter. Individualized growth assessment for fetal and neonatal evaluations. Am J Obstet Gynecol 2018.
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estimates of the coefficients c, k, and s. 89 These coefficient estimates can be obtained from linear relationships between the growth velocity and c as well as between c and s. The coefficient k can be considered a constant 90 (see the Glossary for more details). (5) Third-trimester size trajectories. To generate third-trimester size trajectories for each individual fetus, size models specified from second-trimester growth velocities are used ( Figure 2) . 89, 90 These size trajectories represent individualized size standards because they are derived from estimates of growth potential in the fetus being studied (each fetus is its own control). They indicate what the size of a specific parameter should be if the fetus is growing normally, as is assumed to be the case in the second trimester.
Predicted values for measured anatomical parameters can be directly calculated from their respective size models. For estimated parameters (eg, estimated fetal weight), size models for all of the directly measured parameters used to estimate the desired parameter can give predicted values at any given time point. This set of predicted values is then mathematically transformed into the predicted value for the parameter using an estimation function. 21 Deviations from the predicted trajectory reflect differences between predicted and measured average growth rates for intervals starting at the beginning of the third trimester to any subsequent time point. These IGA concepts have been verified in 4 previous studies. (Figure 3) . 82 This outcome parameter can be used to detect abnormal growth outcomes that express themselves differently in different individuals. 82, 95, 98 Average pathological growth potential realization index apGPRI Average pGPRI value for a set of anatomical parameters. This composite parameter provides a comprehensive measure of neonatal growth pathology.
Pathological modified neonatal growth assessment score pNGAS Difference between the reference range boundary and the modified neonatal growth assessment score measurement (Figure 4 ). 89 The pNGAS provides a comprehensive assessment of neonatal growth outcome based on multiple anatomical parameters weighted for their importance in detecting abnormal growth outcomes.
Deter. Individualized growth assessment for fetal and neonatal evaluations. Am J Obstet Gynecol 2018. (Figure 2) . 94 This parameter provides a measure of growth pathology for individual anatomic parameters at specified time points.
Anatomical parameter prenatal growth assessment score apPGAS Average pathological percent deviation for a single anatomic parameter during the third trimester. 94 This score provides a measure of growth pathology during the third trimester for individual anatomical parameters.
Individual composite prenatal growth assessment score icPGAS Average pathological percent deviation for a set of anatomical parameters at a specific time point. 94 This score provides a way to evaluate growth abnormalities that manifest themselves differently among fetuses.
Fetal growth pathology score FGPS Average pathologic percent deviation for all available anatomical measurements at specific time points in the third trimester ( Figure 6 ). 82 The FGPS measures growth pathology found in the third trimester using all anatomical parameters and time points. Percent deviations from normally growing fetuses contain random variability because of measurement errors, modeling errors, and intrinsic biological control variability, the latter probably related to factors affecting an individual's ability to follow a specified trajectory. However, these variability sources have only a small effect as indicated by the narrow reference ranges of the percent deviations in fetuses with normal neonatal growth 
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This score represents the degree of growth pathology in the third trimester. In this example, 4 size parameters (head circumference, abdominal circumference, femur diaphysis length, estimated fetal weight) are being used to evaluate fetal growth at 30, 32, 34, and 37 weeks (menstrual age). The cumulative moving average of the e%Dev p values for these specific size parameters is designated the FGPS 1. 82 A, As follows:
All e%Dev p values available at 30 weeks (At1, all anatomical parameters at time point 1 included) (gray shaded area) were averaged to give the FGPS1, which was 0% (interpreted as normal growth). This process was repeated at 32 weeks (At2), which included all measurements available (gray shaded area, at both 30 and 32 weeks). The values were averaged to give the FGPS1 value of e1.23%. This signifies that growth restriction has occurred. This process was repeated at 34 weeks (At3), which included all measurements available (gray shaded area, at 30, 32, and 34 weeks). The values were averaged to give the FGPS1 value of e0.85%. This signifies that growth has improved. This process was repeated at 37 weeks (At4), which included all measurements available (gray shaded area, at 30, 32, 34, and 37 weeks). The values were averaged to give the FGPS1 value of e1.53%. This signifies that growth restriction has worsened. All negative pathological percent deviations represent growth pathology (red font).
B, Serial calculations of the FGPS1 (At1, At2, At3, At4) for a single fetus in the third trimester are presented in the plot. The four scores correspond to the data shown in Figure 6A . The horizontal dashed line represents the lower boundary of the negative FGPS1 reference range.
AC, abdominal circumference; %Dev p , pathological percent deviation; EFW, estimated fetal weight; FDL, femur diaphysis length; FGPS, fetal growth pathology score; HC, head circumference. Patterns of fetal growth restriction during third trimester using FGPS Different third-trimester patterns of the FGPS1 were observed in 73 small-for-gestational age fetuses with confirmed postnatal growth restriction. Each fetus had an abnormal third trimester: FGPS1 and an abnormal average pathological growth potential realization index value as a neonate. Seventy of the 73 cases (95%) could be classified into 1 of 5 patterns that are distinct, few in number, seen repeatedly, and have plausible biological interpretations.
101
FGPS1 values are plotted for individual fetuses as a function of menstrual age (black dots).
Pattern 1. There is a constant decline in the FGPS1 with advancing menstrual age. This pattern was observed in 37% of smallfor-gestational-age fetuses (27 of 73). Pattern 2. This fetus had several FGPS1 values of zero, indicating that the fetus was following its own expected growth trajectory. However, fetal growth restriction developed at the last examination (36 weeks). This pattern was observed in 27% of small-for-gestational-age fetuses (20 of 73). Pattern 3. There was an initially very low FGPS1 that leveled off and remained approximately constant in subsequent thirdtrimester examinations. This pattern was observed in 12% of small-for-gestational-age fetuses (9 of 73). Pattern 4. After an initial low FGPS1, there was evidence of recovery followed by subsequent worsening of the growth restriction process. This pattern was observed in 11% of small-for-gestational-age fetuses (8 of 73). Pattern 5. The initial low FGPS1 was followed by a continuous regression toward normal during the latter part of the third trimester. This pattern was observed in 8% of small-for-gestational-age fetuses (6 of 73).
FGPS1, fetal growth pathology score 1. outcomes. 89 Furthermore, percent deviations are independent of differences in growth potential and trajectory shapes and have been shown to be proportional to the difference in expected and measured average thirdtrimester growth velocities 84 . Therefore, they are true measures of growth (not size), and values for different anatomical parameters can be combined to create composite growth measures. 94 (7) Prediction of anatomical birth characteristics. Because birth is just the endpoint of the third-trimester size trajectory, the expected size of any anatomical parameter at birth (if prenatal and postnatal measurements are available) can be obtained with the appropriate fetal parameter-specific size model obtained during pregnancy. However, this requires selection of a birth age, and empirical studies have shown that fetuses delivering after 38 weeks (menstrual age) demonstrate 
Individualized Growth Assessment Program
This freely available software uses individualized growth assessment to evaluate changes in fetal size parameters over time by comparing current and expected size trajectories. Actual measurements are compared with third-trimester size predictions, based on second-trimester size models that have been previously established for the individual fetus (each fetus being its own control). iGAP can be found at https://igap.research.bcm.edu. ajog.org Expert Reviews minimal growth after 38 weeks, which we have designated as growth cessation in cases with normal neonatal growth outcomes. 95 Therefore, IGA uses the actual birth age for deliveries at or before 38 weeks, menstrual age, and 38 weeks, menstrual age, for deliveries after 38 weeks.
Individualized growth assessment does not compare measured birth characteristics with group standards but rather to what these measurements should have been if growth in the designated fetus was normal. The statistic carrying this comparison information is the growth potential realization index (GPRI) (Figure 4) , defined as the ratio of the measured value to the predicted value multiplied by 100 [ideal value ¼ 100%]. 95, 96 For some anatomical parameters, there are systematic measurement errors because of differences in the prenatal and postnatal measurement procedures (eg, prenatal abdominal circumference vs neonatal abdominal circumference; predicted birthweight vs measured birthweight). 97 The predicted values for these parameters are corrected for such systematic measurement errors before GPRI calculation. 95, 97 GPRI values have been shown to be proportional to the difference between the expected and measured average third-trimester growth velocities so are measures of growth, not size. 84 Past studies indicate that GPRI values are independent of differences in growth potential, age at delivery, growth cessation, and systematic measurement errors. 84 Figure 5 ). This score is calculated from a linear function of Parameter selection screen
The user must select a combination of 4 parameters: profile diameter selection, weight estimation selection, mPGAS selection, and normal growth limit selection. Once this set of parameters is selected by the user, IGA analysis is initiated by clicking on Processed Fetal Data.
IGA, individualized growth assessment; mPGAS, modified prenatal growth assessment scores. 
Expert Reviews ajog.org
weighted GPRI values for weight, thigh circumference, abdominal circumference, head circumference, and crownheel length. The weighting factors were obtained using principal components analysis and indicate the relative importance of each anatomical parameter in separating growthrestricted, normal, and macrosomic neonates. Such a separation has been made with an accuracy of 96.9%. 81 Concepts of abnormal fetal/neonatal growth assessment.
(1) Detection and quantification of growth abnormalities. The primary objective of IGA is to identify normal and abnormal fetal/neonatal growth outcomes. Accordingly, measurements outside the parameter-and agespecific 95% range for fetuses/neonates 89 is considered abnormal, even if the clinical neonatal outcomes are apparently normal.
The magnitude of a growth abnormality is expressed by the difference between the measurement and the upper, or lower, boundary of the reference range. Because the 4 fundamental measures of growth are the second-trimester growth velocity, the percent deviation, the GPRI, and the mNGAS, these differences have been given the following designations:
Abnormal growth velocity score (AGVS). 83 Pathological percent deviation (% Dev p ) (Figure 3 ). 82 Pathological GPRI (pGPRI) (Figure 4) . 82, 98 Pathological mNGAS (pNGAS) (Figures 5 and 6 ).
Positive and negative values denote those above and below the reference range, respectively. Measurements within their reference ranges are assigned a difference value of zero because they do not signify a growth abnormality. 82, 99, 100 (2) Specific growth pathology parameters. Individualized growth assessment evaluates growth abnormalities using specific growth parameters in the second and third trimesters (Table 2 ) and at birth (Table 3) .
FIGURE 12
Processed fetal data screen This screen summarizes ultrasound data for several fetal size parameters at each scan date and menstrual age. (Figures 7 and 8) . Concordance between fetal and neonatal growth evaluations Individualized growth assessment has the ability to evaluate third-trimester growth and neonatal growth outcomes separately. However, the anatomical parameters evaluated and sources of error are not the same in these 2 assessment periods. Some parameters have to be estimated (eg, prenatal: measured and predicted weight; neonatal: predicted weight and predicted crown-heel length), while others are directly measured. Therefore, it is very unlikely that third-trimester and neonatal growth assessments will agree by chance.
If the same wrong classification (eg, normal vs abnormal) is made, this would require that all sources of error operate in such a way as to cancel each other out so that the same wrong answer is obtained. This possibility is so remote that we consider concordance between individualized thirdtrimester and neonatal growth evaluations provides the strongest evidence for the presence or absence of growth pathology.
FIGURE 13
Model validation/second-trimester growth evaluation screen
On the left-hand side, data for start point, second-trimester growth velocity, and the model prediction at 28 weeks are presented. Such data are used to detect abnormal values that would result in poor model performance. The right side of the screen depicts the growth velocity measurements compared with their respective reference ranges and calculation of the abnormal growth velocity scores. Growth summary screen Several size parameters are summarized for an individual fetus (in this example, the fetus is normally grown). Red dots indicate the measurements used to calculate second-trimester growth velocities. Rossavik models generate expected size trajectories, and actual measurements (black dots) are superimposed on each curve for different size parameters (eg, head circumference). The blue shaded areas represent the range of normal variation based on fetal growth in pregnancies with confirmed normal neonatal growth outcomes. The graph in the lower-right corner presents the FGPS, calculated at different time points in the third trimester. For this fetus, the dots are on the zero line because there is no growth pathology present.
FGPS, fetal growth pathology score.
ajog.org Expert Reviews long-term neurobehavioral development. Therefore, the iGAP implementation of IGA cannot provide all the tools needed for the clinical care of fetuses with growth abnormalities. However, the software could be introduced as a secondary assessment of fetuses at risk for growth restriction. No studies of its use in macrosomia are presently available.
Practical implementation of individualized growth assessment in clinical obstetrics software
In 2016, a freely available Internet-based software application (iGAP) developed by our team was introduced to allow personalized analyses of fetal growth based on IGA principles. For a given pregnancy, iGAP software ( Figure 9 ) provides a comparison of measured and predicted third-trimester measurements using each fetus as its own control.
The growth analysis tools of iGAP are compatible with multiple computer platforms (Windows, Mac, or Linux) and current Internet browsers. More information about the Health Insurance Portability and Accountability Act, data security, and technical specifications of iGAP are available at the software website (https://igap.research.bcm.edu/). Once a software registration request has been received, the new user will receive a confirmatory e-mail with sign-on instructions generally within no more than 1 business day.
All parameters described in this article, including the model for fetal growth, model coefficients, predicted size trajectories, and the indices used to assess fetal/neonatal growth are available in iGAP. The program includes easy-tofollow instructions, video tutorials, measurement definitions, glossary of terms, and frequently asked questions ( Figure 10 ).
Readers are encouraged to review 3 training videos that have been prepared on the iGAP website to review basic concepts about individualized growth assessment (17 minutes, 6 seconds), explain how iGAP software is used on a normally growing fetus (12 minutes, 7 seconds), and demonstrate how it can be used to assess abnormal growth (10 minutes, 45 seconds).
Specifically, iGAP provides data analysis templates for the following:
Parameter selection: provides a choice of parameters for IGA including weight estimation procedure, modified prenatal growth assessment score, and normal growth limit (Figure 11 ). Processed fetal data: presents the biometric data to be analyzed (Figure 12 ). apPGAS, anatomical parameter prenatal growth assessment score; FGPS, fetal growth pathology scores; mPGAS, modified prenatal growth assessment score. Second-trimester model specification: to determine the model coefficients that allow generation of predicted growth trajectories. Model validation: to evaluate characteristics of growth start points and second-trimester growth velocities as well as the ability of the model to predict a normal value at 28 weeks) ( Figure 13 ).
Second-trimester growth evaluation: to compare growth velocities with their reference ranges ( Figure 13 ). Growth summary: plots of individual anatomical parameter size trajectories and the FGPS (Figure 14) . Third-trimester growth evaluation: tables that give percent deviations, PGAS, and FGPS at different time points in the third trimester for each anatomical parameter ( Figure 15 ). Anatomical parameter graph display (eg, head circumference): provides the results of IGA analysis in graphic form for each anatomical parameter. Neonatal growth assessment: table that gives the predicted and measured birth characteristics as well as growth potential realization indices for all FIGURE 16 Neonatal growth assessment screen
The measured and predicted values for neonatal birth characteristics and their associated GPRIs are presented for the anatomical parameters measured postnatally. The GPRI values are compared with their reference ranges and the pGPRI values calculated. The predicted values depend on the gestational age at delivery being used, which can be selected in the lower-left-hand corner (growth cessation age, birth age). The averages for pGPRI values (gray shaded row) are presented below the pGPRI columns. If appropriate data are available, the mNGAS is presented in the lower-right-hand corner of the screen. The mNGAS is compared with its reference range to give the pNGAS. The measures of pathology (pGPRI, average pGPRI, pNGAS) are all zero in this example, indicating normal neonatal growth outcome.
GPRI, growth potential realization index; mNGAS, modified neonatal growth assessment score; pGPRI, pathological GPRI; pNGAS, pathological neonatal growth assessment score. ajog.org Expert Reviews anatomical parameters measured. pGPRIs and their average are also presented. If appropriate data are available, the mNGAS is calculated (Figure 16 ).
The user can interactively select which second-trimester measurements are used to specify size models. Recently the implementation of IGA for the detection of late-onset fetal growth restriction (using iGAP software) was independently validated by Simcox et al 93 in a longitudinal prospective cohort study of 115 pregnancies. An evaluation of fetal growth restriction using iGAP is demonstrated in Figure 17 .
Unlike conventional methods to assess fetal growth, iGAP provides a means to easily interpret complex information (eg, repeated biometric measurements and multiple composite anatomic parameters). For a given fetus/neonate, the advantages of iGAP include the following: (1) estimation of growth potential using multiple anatomical parameters, (2) prediction of future growth, (3) identifying evolutionary patterns of fetal growth pathology during the third trimester, and (4) accurate classification of growth outcome in the neonate.
Conclusions
Individualized growth assessment provides a comprehensive method for identifying third-trimester fetal and/or neonatal growth abnormalities based on an individual's growth potential. The clinical use of individualized growth assessment to characterize abnormal growth and its relationships to physiological changes, perinatal complications, and long-term disabilities warrants further study. Earlier detection and improved monitoring of pathological growth processes provide clinicians with valuable information to determine the optimal frequency of antenatal testing or implementation of timely therapeutic interventions.
-

Glossary of terms
Abnormal growth velocity score (AGVS). Measured second-trimester growth velocities for each anatomical parameter (eg, abdominal circumference, femur diaphysis length) are compared with their appropriate reference ranges. Measurements within these ranges are assigned AGVS values of zero because no growth abnormality is present. For measurements above or below their respective reference ranges, the AGVS values are the differences between the measurements and the appropriate anatomical parameter-specific reference ranges.
Anatomical parameter prenatal growth assessment score (apPGAS). This type of prenatal growth assessment score measures the growth pathology in individual growth parameters (eg, head circumference) during the third trimester. It is the average of pathological percent deviation (%Dev p ) values obtained at all third-trimester time points.
Anatomical parameter (P). This is a fetal biometric parameter that can be 1-, 2-and 3-dimensional and is used to characterize different aspects of normal fetal growth and to detect growth abnormalities. Examples include biparietal diameter (1 dimensional), abdominal profile area (2 dimensional), and fractional limb volume (3 dimensional). Coefficient c and coefficient c*. These coefficients of the Rossavik model are strongly related to second-trimester growth velocity. They are thought to represent known and unknown controllers of normal fetal growth. Coefficient c is determined by regression analysis; if this regression analysis is carried out using a fixed value of k, coefficient c is now designated as coefficient c*.
Coefficient k. This coefficient represents the characteristics (including dimensionality) of the anatomical parameter being measured. It is considered to be constant from fetus to fetus for a given anatomical measurement and has values that have been determined in fetuses with normal neonatal growth outcomes.
Coefficient s and coefficient s*. These coefficients of the Rossavik model represent factors that control fetal growth. Their major effect is observed at the end of the third trimester. Coefficient s is determined by regression analysis; if this regression analysis is carried out using a fixed value of k, coefficient s is now designated as coefficient s*. Fetal growth pathology score (FGPS). This score provides a quantitative measure of growth pathology and addresses a number of confounding variables present in longitudinal growth studies. The FGPS represents the average of available positive or negative pathological percent deviations [%Dev p ] at the end of each ultrasound examination in the third-trimester (cumulative moving average) (see Figure 7) . The FGPS can be used to detect growth abnormalities; estimate the onset, duration, and magnitude of pathological growth processes; and identify different growth abnormality patterns.
Fetal weight estimation. Fetal weight cannot be measured directly using ultrasound technology. Weight estimates are obtained from single anatomical measurements or a set of anatomical measurements. Predicted values for each anatomical parameter are obtained using the appropriate second-trimesterespecified Rossavik size model. A predicted weight estimate is calculated using these predicted values and the weight estimation function. The measured weight estimate is calculated using the age-specific ultrasound measurements themselves and the same function.
Fractional polynomials. Fractional polynomials are a class of mathematical functions that have power values that are not limited to whole numbers. This property gives these functions great flexibility in modeling fetal size data.
Individual composite prenatal growth assessment score (icPGAS). This type of prenatal growth assessment score measures growth pathology at a single time point in the third trimester. It is the average of the pathological percent deviation (%Dev p ) values obtained at a specific time point for a set of anatomical parameters used to evaluate different aspects of fetal growth (eg, head circumference, abdominal circumference, femur diaphysis length, estimated fetal weight).
Individualized growth assessment (IGA). A method for the evaluation of fetal growth and neonatal growth outcome in which each fetus is its own control, based on estimates of individual growth potentials. Third-trimester growth measurements and birth characteristics are compared with their predicted values obtained using size models specified in the second trimester. Individualized Growth Assessment Program (iGAP). This Internet-based software implements the concepts of individualized growth assessment for clinical use or research. The application is freely available at https://igap.research.bcm.edu/.
Individualized size trajectories. Third-trimester predicted values for an anatomical parameter constitute its expected size trajectory in a given fetus. It is specific for that fetus and is unaffected by biological differences between fetuses. Only the second-trimester growth velocity and random modeling/measurement errors alter its shape. If second-trimester growth is normal, it is the most appropriate standard for evaluating subsequent third-trimester measurements.
Modified prenatal growth assessment score (DPGAS, ePGAS). The PGAS is a composite size parameter that averages pathological percent deviations (%Dev p ) obtained in the third trimester. Macrosomia is evaluated using þPGAS values, whereas growth restriction is evaluated using ePGAS values. Serial calculations of þPGAS and ePGAS provide a quantitative means for characterizing third-trimester growth pathology. Modified prenatal growth assessment score reference ranges. Age-specific reference ranges [95%] for modified prenatal growth assessment scores have been determined during the third trimester in fetuses with normal neonatal growth outcomes. Values outside the appropriate ranges are considered to be abnormal and indicative of a growth disorder. Percent Deviations (%Dev). This statistic is used to compare third-trimester anatomical measurements to their predicted values: %Dev ¼ [(measured value e predicted value)/predicted value] Â 100]. The ideal value for a percent deviation is zero. Once all anatomical measurements are converted to percent deviations, they are in a common form that can be combined to form composite size parameters.
Pathological percent deviation (%Dev p ). Pathological percent deviation is the part of the percent deviation above the upper limit (þp% Dev) or below the lower limit (ep%Dev) of its age-specific reference range. Percent deviations within the reference range are assigned % Dev p values of zero because no pathology was found. Pathological percent deviations quantify the magnitude of the growth pathology.
Rossavik size model. This is an equation that was empirically derived and is used to characterize fetal growth. The formula is the following: P ¼ cðtÞ kþsðtÞ P is the anatomical parameter c, k, and s are the model coefficients (meaning and method of calculation are explained in this Glossary) t is the duration of growth, which is menstrual age e start point
The size model can be specified for different parameters (eg, abdominal circumference, femur diaphysis length, biparietal diameter, estimated fetal weight, etc). It is derived from growth velocity measurements calculated using at least 2 ultrasound examinations in the second trimester of pregnancy, separated by at least 2e3 weeks.
Second-trimester Rossavik size model specification. This size model can be specified if values for coefficients c, k, and s are known. B Coefficient k is a known constant whose value depends on the characteristics of the anatomical parameter being measured. B An estimate of coefficient c* can be obtained from the slope of the second-trimester growth curve (growth velocity). B Predicted s* values (used as estimates of coefficient s*) can be obtained from estimates of coefficient c* derived from second-trimester slopes. The precise method for calculating these coefficients is available. 89 Moreover, the Individualized Growth Assessment Program calculates these coefficients based on the results of ultrasound examinations, obviating the need for clinicians to perform manual calculations using regression analysis. Second-trimester growth velocity (slope). In the second trimester, the growth of all fetal biometric parameters, which are unidimensional (eg, abdominal circumference, femur diaphysis length, biparietal diameter, etc), is linear. It is believed that such linearity of growth in the second trimester is due to the fact that fetal nutritional requirements are easily met. This concept can be extended to 2-and 3-dimensional parameters by appropriate mathematical transformation of the data. The Individualized Growth Assessment Program performs these calculations automatically. Start Point (SP). Growth of a given anatomical parameter can begin only when it first appears in embryological development (start point). Start points for anatomical parameters in a given fetus are determined by extrapolating the straight lines fitted to secondtrimester measurements back to the point at which the lines cross the time (menstrual age) axis. It may be necessary to transform the measurements prior to fitting to use linear functions (eg, cube root of fractional thigh volume or square root of abdominal profile area). Third-trimester predicted values. Second-trimesterespecified Rossavik size models can be used to calculate predicted values for anatomical parameters at any time point in the third trimester. Usually the time points chosen are those for which sonographic measurements of the anatomical parameter are available.
